Seeking Alpha

Sarepta (SRPT -0.5%) says it's entered into a Clinical Trial Agreement with the National...

Sarepta (SRPT -0.5%) says it's entered into a Clinical Trial Agreement with the National Institute of Allergy and Infectious Diseases to conduct a Phase I study with its experimental flu vaccine and lead drug candidate, AVI-7100. The drug has  the potential to address a broad-spectrum of influenza viruses, including Tamiflu-resistant virus strains. Separately, The Street's Adam Feuerstein called the stock a top biotech pick for 2013, saying its Duchenne muscular dystrophy treatment, eteplirsen, and is poised for accelerated approval.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|